Recently, compared with conventional chemotherapy, immune checkpoint inhibitors, especially those targeting programmed cell death protein 1 (PD-1), have been shown to effectively prolong the overall survival (OS) of patients with recurrent and advanced NSCLC [3,4,5]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.